Trial Profile
Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Sorafenib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 30 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 22 Mar 2019 Planned End Date changed from 1 Apr 2025 to 30 Jun 2022.
- 22 Mar 2019 Planned primary completion date changed from 1 Apr 2024 to 30 Jun 2021.